Benchmark Holdings PLC Notice of Q2 and Interim Results (4987Y)

TIDMBMK

RNS Number : 4987Y

Benchmark Holdings PLC

05 May 2023

5 May 2023

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

Notice of Q2 and Interim Results

Results presentations

Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will announce its Q2 and Interims results, for the three and six month period ended 31 March 2023, on Tuesday, 23 May 2023.

Presentation for analysts and institutional investors at 08.00 UK

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a presentation for analysts and institutional investors on the day at 08.00 UK time.

A live webcast of the presentation will be available for analysts and investors to join remotely at the following link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230523_3

Equity Development webcast at 12.00 UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a second webcast for retail investors and wealth managers on the day at 12.00 UK time. The webcast is open to all existing and potential shareholders.

To register please visit: https://www.equitydevelopment.co.uk/news-and-events/benchmark-2qresults-presentation-23may2023

A recording of the presentation will be available after the event on the Equity Development website .

Enquiries

 
 For further information, please contact: 
  Benchmark Holdings plc                         Tel: 0114 240 9939 
  Trond Williksen, CEO 
  Septima Maguire, CFO 
  Ivonne Cantu, Investor Relations 
 
 
  Numis (Broker and NOMAD)                       Tel: 020 7260 1000 
  Freddie Barnfield, Duncan Monteith, 
   Sher Shah 
 
  MHP                                            Tel: 020 3128 8004 
  Katie Hunt, Reg Hoare, Veronica Farah      benchmark@mhpgroup.com 
 
   Equity Development                            Tel: 020 7065 2692 
   Hannah Crowe

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORAIMPTMTBMBLJ

(END) Dow Jones Newswires

May 05, 2023 02:00 ET (06:00 GMT)

Benchmark (LSE:BMK)
Historical Stock Chart
From Jun 2024 to Jul 2024